

Special Issue

The Emerging Role of Multiplexed Imaging for Cancer Diagnosis and Therapy

Message from the Guest Editors

This Special Issue aims to highlight the latest advancements and applications of multiplexed imaging techniques in cancer diagnosis and therapy. Multiplexed imaging allows for the simultaneous visualization and quantification of multiple biomarkers, enhancing the accuracy and comprehensiveness of cancer diagnostics and treatment monitoring. The scope of this Special Issue includes developments in bioluminescence, fluorescence, and photoacoustic imaging technologies, as well as advanced applications of CT, MRI, PET, and SPECT multiplexed imaging for different types of cancer treatments or theragnostics. Topics of interest also include novel contrast agents, hybrid imaging techniques, and the integration of these modalities with therapeutic interventions. Contributions exploring the clinical translation of these technologies, their impact on personalized and/or pan-anticancer therapy, and their roles in early detection, staging, and monitoring treatment response are particularly welcome.

Guest Editors

Dr. Li Liu

Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, TX, USA

Prof. Dr. Yicheng Ni

Department of Radiology, Affiliated Zhongda Hospital, Southeast University, Nanjing, China

Deadline for manuscript submissions

closed (30 April 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/211692

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)